Avacta Share Discussion Threads

[74tom] 10/10/2019 08:50

@Babbler, we both know how long it takes to develop a new drug from inception to FDA license etc! In the meantime they have substantial overheads to cover, plus any R&D costs not directly linked to the deals. The prelims will tell us more on cash burn but I�d be very surprised if it had reduced by a material amount.

[babbler] 10/10/2019 08:43

I thought that's the point of the last few rns? Other pharma are funding them and they get a cut of the sales?

[74tom] 10/10/2019 08:31

It wont re-rate just on that RNS... They had 11.7m cash at 31st January and had burned 4.2m in the previous half year, so based on the burn continuing at around 700k per month (a fair assumption with AVCT), cash at 31 July would be around 7.5m, and current cash will be around 6m.

They last raised cash in July 2018 when the cash balance was 5.2m, and this placing was announced 6 days after a therapeutics partnership was signed!

Summary: a very disappointing year to date with no newsworthy updates on either LG, Tufts, Moderna or any other previously announced deal. Id say a high likelihood of a placing between now and Christmas, and only after such placing would I consider investing again here.

[bumpa33] 10/10/2019 08:21

nicely timed for the investor presentation this evening. Most pertinent point perhaps is that billion $ Pharma do not usually do deals with companies with a supposed question mark over their finances.

[babbler] 10/10/2019 08:12

Nice slow re-rate back into 30s...doing what mtfb should have.

[toffeeman] 10/10/2019 08:12

will need more of these to get a decent lift

[genierub] 10/10/2019 08:08

No quote given on buying. Extremely positive sign for where this could be heading.

[bumpa33] 10/10/2019 07:20

Collab with a $1.6B Pharma, Swiss ADC Therapeutics.

[chilly0] 08/10/2019 22:42

AGM soon. That will be fun ?

[chilly0] 08/10/2019 22:41

Well it plain to see. Risky share

[escapetohome] 08/10/2019 22:27

Avacta: An unacceptable performance.

I dont mince words.

[chilly0] 08/10/2019 22:25

Well done you deserve a break

[dave4545] 25/9/2019 08:52

Interesting chart.

No move and at a critical level. If it starts to move up from here then it could really bounce well. But if it dropped below 20p then the chart looks poor.

mm's want almost full offer to buy though so strong online, it got chased into the 40's earlier this year.

If it goes blue I'll take a position

[danatkins] 12/9/2019 15:35

I also think we will have material news before the proverbial begging bowl comes out. Our CEO also mentioned raising money from Asia and I got the impression he was not happy with last round of finance. Of course take that as it is a large pinch of salt

[daymer58] 12/9/2019 14:54

AgreeHowever we must remember existing license deal have further payment in stages and the company did mentioned " new discussions " Still think the sector is grossly oversold and stocks like Avacta with a unique accelerated pipeline will start to attract some new institutional shareholders.Read across valuation of US biotech oncology stocks vs Avacta makes it ridiculous cheap and as a shareholder alas also a bid target.Roche, Novartis etc are all moving inAsians are signing deals, we got LG , who's next

[the drewster] 12/9/2019 13:38

The risk remains cash management ... value inflection points mean nothing if you have to go begging to the institutions for more cash, which they will dictate the terms on, not the company.

[escapetohome] 12/9/2019 13:14

Good sum up.

No way they are getting my shares at this price!

Keep trying , I doubt youre getting many.

[daymer58] 12/9/2019 12:56

Big move in the US Biotech/ health care sector last night.Goldman's strong upgrade in Bicycle Therapeutics 99% upside, stock moved 28%.Very good read across to AVCT . Expect further moves in the Antibody mimetic platform sector.We got two US IPO's in the oncology sector coming up, expect further deals from AVCT, the majors are all over this sector, stock massively oversold.